Why “Pass-Through” Doesn’t Always Mean What You Think
By
For years, pass-through pricing has been marketed as the gold standard of pharmacy transparency. Employers hear the term and assume it guarantees clarity, fairness, and alignment. Brokers hear it and often check the box; confident they’ve solved the PBM problem.
But here’s the uncomfortable truth: Pass-through does not automatically mean transparent. And it certainly does not mean cost containment.
Understanding the difference matters more now than ever, especially as pharmacy spend continues to outpace every other category in employer health plans.
What “Pass-Through” Is Supposed to Mean
In its simplest form, pass-through pricing suggests that a PBM charges the employer exactly what it pays pharmacies and manufacturers, then earns revenue through clearly disclosed administrative fees.
On paper, that sounds straightforward. No spread pricing. No hidden margins. Clean math.
In reality, pass-through is often a pricing structure, not a philosophy. And structure alone does not eliminate misaligned incentives.
Where the Definition Breaks Down
Most employers assume pass-through means all dollars are passed through. That assumption is rarely correct.
Here’s where things get murky.
1. Not Everything Is Included
Many contracts define pass-through narrowly. Ingredient cost and dispensing fees may be passed through, while other revenue streams remain untouched.
Common exclusions include:
- Manufacturer administrative fees
- Data and rebate aggregation fees
- Specialty pharmacy margins
- Formularies designed around rebate optimization, not lowest net cost
The result is transparency in one lane, opacity in the others.
2. Rebates Still Distort Decisions
Even in pass-through models, rebates often remain central to PBM economics. That creates a quiet conflict.
When revenue depends on rebate volume, formularies tend to favor higher list-price drugs. Employers may see rebates flowing back but still experience rising overall spend.
Passing rebates through does not eliminate the incentive problem. It just makes it harder to spot.
3. Contract Language Matters More Than Labels
Two PBMs can both advertise pass-through pricing and deliver wildly different financial outcomes.
Why? Because the real story lives in:
- Definitions
- Exclusions
- Audit rights
- Fee escalation clauses
- Specialty carve-outs
Without contract scrutiny, “pass-through” becomes a marketing term rather than a meaningful protection.
Why This Matters for Employers and Brokers
Pharmacy is no longer a back-office benefit. It is a financial risk category with fiduciary implications.
Employers are increasingly expected to demonstrate oversight of prescription drug spend, not just acceptance of industry norms. Brokers are expected to help interpret complexity, not simply select vendors.
When pass-through pricing is accepted at face value:
- Employers believe they have transparency when they do not
- Brokers miss opportunities to add strategic value
- Cost drivers remain hidden until renewal or worse, mid-plan-year
The Better Question to Ask
Instead of asking, “Is this PBM pass-through?” the better question is: “What incentives still exist in this model, and who benefits from them?”
True transparency means understanding:
- Where every dollar originates
- Where it flows
- Who profits at each step
- Whether those incentives align with the employer’s goals
That level of clarity does not come from a pricing label. It comes from intentional design, independent oversight, and advocacy that puts the plan sponsor first.
Moving Beyond Labels
Pass-through pricing is not inherently bad. In many cases, it is an improvement over legacy spread models.
But it is not a finish line.
For employers and brokers serious about cost reduction, financial impact, and long-term sustainability, pharmacy strategy must go deeper than contract buzzwords. It requires asking harder questions and being willing to challenge comfortable assumptions.
Because in pharmacy, what you think you’re getting and what you’re actually paying for are often very different things.